Sellas Life Sciences Group, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
State Street Corporation has disclosed beneficial ownership of 7% of Sellas Life Sciences Group Inc.'s common stock as of June 30, 2026.
NASDAQ
Vanguard Capital Management has reported beneficial ownership of 9,666,278 shares, representing 5.19% of the class, in SELLAS Life Sciences Group Inc.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in SELLAS Life Sciences Group Inc. due to an internal realignment.
NASDAQ
Anson Funds and its affiliates have reported a 4.9% passive beneficial ownership stake in Sellas Life Sciences Group, Inc. as of December 31, 2025.
NASDAQ
Highbridge Capital Management has reduced its beneficial ownership in SELLAS Life Sciences Group, Inc. from 6.0% to 3.7% through warrant exercises.
NASDAQ
Anson Funds Management LP and affiliated entities have reported a 5.7% beneficial ownership stake in Sellas Life Sciences Group, Inc., totaling 6,032,938 shares.
NASDAQ
SCHEDULE 13G: BlackRock Discloses 5.4% Stake in SELLAS Life Sciences
BlackRock, Inc. has reported a 5.4% beneficial ownership stake in SELLAS LIFE SCIENCES GROUP INC, holding 5,686,886 common shares.
NASDAQ
Anson Funds Management LP and related entities have disclosed a 4.9% beneficial ownership stake in Sellas Life Sciences Group, Inc. common stock.
NASDAQ
The Vanguard Group has reported a 6.7% beneficial ownership stake in SELLAS Life Sciences Group Inc., primarily through warrants, held for investment purposes.
NASDAQ
Anson Funds Management LP and its affiliates have reported a passive beneficial ownership of 8.3% in Sellas Life Sciences Group, Inc., totaling 7,579,095 shares of common stock.